KNSA — Kiniksa Pharmaceuticals International, plc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1730430 ·
United Kingdom
Last close
$74.34
Market Cap
$3.44B
52W High
$82.94
52W Low
$46.10
ADV30
1,024,413
Next earnings
2026-10-27
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 243,600,000 | 131,959,000 | 27,194,000 | 25,432,000 | 896,110,000 | 175,677,000 | 241,961,000 |
| Mar 2026 | 214,266,000 | 117,893,000 | 29,267,000 | 22,592,000 | 825,280,000 | 189,952,000 | 219,593,000 |
| Dec 2025 | 202,127,000 | 111,152,000 | 19,768,000 | 14,199,000 | 763,633,000 | 165,596,000 | 196,027,000 |
| Sep 2025 | 180,855,000 | 97,291,000 | 24,021,000 | 18,435,000 | 712,333,000 | 174,858,000 | 176,950,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$184,965,000
Investing CF
$-239,065,000
Financing CF
$37,740,000
CapEx
$-2,128,000
Dividends Paid
—
Buybacks
$-11,055,000
EPS Diluted TTM
$0.97
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-414,114,000
Inventory
$70,930,000
Receivables
$23,490,000
ST Investments
$350,251,000
EBIT TTM
$100,250,000
Pretax Income TTM
$114,252,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$840,848,000
EBITDA
$102,041,000
Free Cash Flow
$126,144,248
Enterprise Value
$5,283,274,240
Total Cash
$525,928,000
Total Debt
$8,897,000
Shares Out
46,303,276
Trailing EPS
$0.99
Book Value
$8.39
ROE
14.0%
ROA
8.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 677,564,000 | 77,221,000 | 59,005,000 | 763,633,000 | 196,027,000 | — | 137,985,000 |
| Dec 2024 | 423,239,000 | -45,616,000 | -43,193,000 | 580,553,000 | 142,117,000 | — | 25,689,000 |
| Dec 2023 | 270,259,000 | -25,196,000 | 14,084,000 | 526,322,000 | 87,483,000 | — | 13,301,000 |
| Dec 2022 | 220,180,000 | 9,773,000 | 183,363,000 | 459,672,000 | 63,523,000 | — | 5,807,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.62
Max Pain — expiry 2026-08-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $75.00 · spot: $74.34 · call volume: 31 · put volume: 80
Expected Move to 2026-08-21:
±$6.85
(9.21%) —
implied range
$67.49 –
$81.19
· ATM straddle on $75.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IDYA | IDEAYA Biosciences, Inc. | $3.42B | $35.50 | — |
| GPCR | Structure Therapeutics Inc. | $3.41B | $48.04 | — |
| ALMS | ALUMIS INC. | $3.49B | $28.25 | — |
| GRTX | Galera Therapeutics, Inc. | $3.38B | $16.28 | — |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.36B | $26.86 | — |
News headlines (Yahoo Finance, 1h cache)
MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth
2026-07-31 15:34 · Yahoo
Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?
2026-07-30 16:20 · Yahoo
Could Kiniksa Pharmaceuticals International (KNSA) Be 16% Overvalued After Raised 2026 Guidance?
2026-07-30 03:15 · Yahoo
Why Kiniksa Pharmaceuticals (KNSA) Is Up 29.6% After Raising 2026 Revenue Guidance And Advancing Pipeline
2026-07-29 22:08 · Yahoo
Kiniksa Pharmaceuticals, Ltd. Q2 2026 Earnings Call Summary
2026-07-28 19:21 · Yahoo
Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down
2026-07-28 15:21 · Yahoo
Kiniksa Reports Strong Q2 Results, Raises 2026 ARCALYST Sales Guidance
2026-07-28 14:09 · Yahoo
Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights
2026-07-28 14:04 · Yahoo
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates
2026-07-28 12:50 · Yahoo
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
2026-07-28 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.